What is COMPASS Pathways?
COMPASS Pathways is dedicated to transforming mental health care by pioneering new therapeutic approaches. The company is at the forefront of developing a novel model of psilocybin therapy, centered around its proprietary COMP360 formulation. This innovative treatment is administered in conjunction with comprehensive psychological support, aiming to address the unmet needs of individuals suffering from mental health challenges who have not responded to conventional therapies. The company's strategic focus on evidence-based innovation positions it as a key player in the evolving landscape of psychiatric treatment.
How much funding has COMPASS Pathways raised?
COMPASS Pathways has raised a total of $578.5M across 5 funding rounds:
Series A
$35.5M
Series B
$80M
Stock Offering
$128M
Debt
$50M
Other Financing Round
$285M
Series A (2018): $35.5M, investors not publicly disclosed
Series B (2020): $80M led by McQuade Center for Strategic Research and Development, Perceptive Advisors, ATAI Life Sciences, Soleus Capital, Skyviews Life Science, Camden Partners Nexus, Able Partners, and Founders Fund
Stock Issuance/Offering (2020): $128M, investors not publicly disclosed
Debt (2023): $50M featuring Hercules Capital
Other Financing Round (2023): $285M backed by TCG Crossover, Logos Capital Partners Sa rl, Aisling Capital, and Vivo Capital
Key Investors in COMPASS Pathways
TCG Crossover
TCG Crossover (TCGX) is a science-driven investment firm focused on advancing disruptive medicines. The company aims to invest in breakthrough therapies that have the potential to transform healthcare. Their target clients include innovators in the pharmaceutical and biotechnology sectors. TCGX is committed to supporting the development of extraordinary medical solutions.
Perceptive Advisors
Founded in 1999 and based in New York, NY, Perceptive Advisors is an investment firm managing around $7 billion in assets, focused on funding innovative healthcare and life sciences technologies.
Founders Fund
Founders Fund invests in the world's most important and valuable companies across all geographies, sectors and stages. The firm's partners have been founders and early funders of companies including PayPal, SpaceX, Palantir, Anduril, Airbnb, Stripe and Facebook. Founders Fund pursues a founder-friendly investment strategy, providing maximum support with minimum interference.
What's next for COMPASS Pathways?
The recent major strategic investment of $285M into COMPASS Pathways, contributing to its overall $578.5M in capital, indicates a strong market validation and confidence in the company's therapeutic model. This significant backing is expected to fuel further research and development, scale clinical trials, and accelerate the pathway to broader patient access for COMP360 psilocybin therapy. The company's trajectory suggests a continued focus on expanding its evidence base and navigating regulatory pathways to establish a new standard of care in mental health treatment.
See full COMPASS Pathways company page
